MEDIA RELEASE - New research on potent HIV antibodies opens up possibilities for HIV prevention and treatment
Embargo: 2 March 2014, at 20:00 South Africa time / 13:00 US Eastern Time
The discovery of how a KwaZulu-Natal woman’s body responded to her HIV infection by making potent antibodies (called broadly neutralising antibodies, because they are able to kill multiple strains of HIV from across the world), was reported today by the CAPRISA consortium of AIDS researchers jointly with scientists from the United States. The study, published in the prestigious scientific journal, Nature, describes how the research team found and identified these antibodies in her blood and then duplicated them by cloning the antibodies in the laboratory. The cloned antibodies were then used in a series of experiments in the laboratory to elucidate the pathway followed by her immune system to make these potent antibodies.
The South African researchers in the CAPRISA consortium, which includes scientists from the National Institute for Communicable Diseases in Johannesburg, the University of KwaZulu-Natal and the University of Cape Town, worked jointly with US partners based at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, and Columbia University in New York, to conduct this research.
Professor Salim S. Abdool Karim, leader of the CAPRISA consortium and President of the Medical Research Council, commented, “The new insights gained from this KwaZulu-Natal woman into immune responses against HIV bring hope for future HIV prevention and treatment strategies. This woman, referred to as CAPRISA 256 (abbreviated to CAP256), is doing well on antiretroviral therapy and continues to attend the CAPRISA clinic regularly.”
Just over a year ago, the same team of South African researchers reported in Nature Medicine (also part of the Nature group of journals) on their discovery relating to two other KwaZulu-Natal women, that a shift in the position of one sugar molecule on the surface of the virus led to the development of broadly neutralising antibodies against HIV. Professor Lynn Morris, who leads the research team at the National Institute for Communicable Diseases (NICD) commented, “In this new publication, we have been able to isolate a broadly neutralising antibody from this CAPRISA volunteer and trace its origins to understand exactly how it arose. This could lead to new HIV vaccine strategies that are able to stimulate the rare precursors of these protective antibodies.”
All HIV infected people respond to HIV by making antibodies. In most patients, these antibodies are not able to kill a wide range of HIV – this is described as a lack of neutralisation breadth. However, in a few infected people, they naturally make antibodies that kill (neutralise) many different kinds of HIV (i.e. they are broadly neutralising antibodies). “Broadly neutralising antibodies have some unusual features,” says Dr Penny Moore, one of the lead South African scientists on the study based at the NICD. “The outer covering (envelope) of HIV has a coating of sugars that prevents antibodies from reaching the surface to neutralise the virus. In this patient, we found that her antibodies had ‘long arms’, which enabled them to reach through the sugar coat that protects HIV.” In this study, the researchers found that these antibodies had ‘long arms’ right at the outset. “We discovered that some HIV antibodies are born with ‘long arms’, requiring less time and fewer changes to become effective in killing HIV, ” said Dr Moore.
The identification and successful cloning of these special antibodies enables the researchers to make sufficiently large quantities for further testing, similar to the way a medicine used to prevent or treat HIV would be tested. “Our goal is to test these antibodies, preferably in combination with other broadly neutralising antibodies, directly in patients with HIV infection or in patients at risk of getting infected,” said Professor Abdool Karim. “But this will take some time as the team is currently planning animal studies as a first step. Broadly neutralising antibodies have previously been shown to be effective in preventing and treating HIV infection in animals, but this has never before been shown in humans.” The future studies on animals and humans are being supported by the Strategic Health Innovation Partnerships (SHIP), a unit of the South African Medical Research Council, with funding from the Department of Science and Technology.
The Minister of Science and Technology, Mr Derek Hanekom, commented: “This study highlights the importance of international scientific partnerships and the contributions of South African researchers to world-class medical science. The Department of Science and Technology is delighted to have contributed funds for this research. We are proud of the South African research team who conducted this ground-breaking study and thank the US partners for their collaboration and support.”
The Minister of Health, Dr Aaron Motsoaledi, pointed out: “Since South Africa has the largest burden of HIV infection globally, we are gratified to see South African scientists, under Professor Abdool Karim’s leadership, undertake research to find solutions that will bring an end to AIDS. We are hopeful that this research takes us one step closer to developing an AIDS vaccine.”
This research was primarily funded by the US National Institutes of Health’s Vaccine Research Center and the South African Department of Science and Technology. The South African researchers also have fellowships from the Wellcome Trust, the Fogarty International Center, the National Research Foundation and the Poliomyelitis Research Foundation.
Media enquiries:
Judith Annakie-Eriksen, Communications Officer, CAPRISA
Tel: +27 (0)82 7821276
Email: AnnakieEriksen@ukzn.ac.za
Aziel Gangerdine, Head of Corporate Communications, MRC
Tel: +27 21 938 0697 Mobile: +27 71 866 9887
Email: Aziel.gangerdine@mrc.ac.za